3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
OTHER_GOV
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Magnetic Resonance Spectroscopy
262
Specimen Handling
253
pembrolizumab
230
Cyclophosphamide
216
Radiotherapy
204
Nivolumab
168
Cisplatin
161
Carboplatin
145
Biopsy
144
Radiosurgery
128
fludarabine
123
Blood Specimen Collection
116
Gemcitabine
111
Paclitaxel
107
Surveys and Questionnaires
106
Standard of Care
102
venetoclax
94
Dexamethasone
93
Bevacizumab
92
Radiation
87
Rituximab
81
Capecitabine
80
Cytarabine
79
Oxaliplatin
77
Drug Therapy
75
Doxorubicin
75
Ipilimumab
73
durvalumab
70
fludarabine phosphate
69
atezolizumab
68
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Alemtuzumab
×
90 days
×
Clear all
NCT06084780
2026-06-05
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled
NCT03821610
2026-05-05
ALL-RIC
University of Birmingham
Phase 2
Active not recruiting
242 enrolled